Keywords
Last Name

Omar Eton, MD

TitleAssociate Professor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionHematology & Medical Oncology
Address820 Harrison Ave
Boston MA 02118
Phone(617) 638-7520
ORCID ORCID Icon0000-0002-9141-553X
Other Positions
TitleActive Staff Privileges
InstitutionBoston Medical Center
DepartmentMedicine

 Research Expertise & Professional Interests
Expertise includes: Preclinical to clinical transitions in Oncology; Phase 1,2,3,... oncology drug development from blank concept page to IRB protocol approval and successful trial execution and final published manuscript; Melanoma; Tyrosine kinase inhibitors; Tumor immunology; Endocrine tumors; and GI tumors. Interests include nanocarriers and cutting edge discovery agents heading to the clinic.

 Self-Described Keywords
  • endocrine cancers (eg thyroid)
  • gastrointestinal tumors
  • mutidisciplinary management of melanoma
 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, Wong ET. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother. 2012 Oct; 12(10):1207-15. PMID: 23082737.
    View in: PubMed
  2. Macarulla T, Cervantes A, Elez E, Rodríguez-Braun E, Baselga J, Roselló S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton O, Fingert H, Tabernero J. Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther. 2010 Oct; 9(10):2844-52. PMID: 20724522.
    View in: PubMed
  3. Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Apr; 67(4):945-54. PMID: 20607239.
    View in: PubMed
  4. Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, Bedikian AY, Lee JE. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J Transl Med. 2010; 8:9. PMID: 20109236.
    View in: PubMed
  5. Lynch TJ, Fenton D, Hirsh V, Bodkin D, Middleman EL, Chiappori A, Halmos B, Favis R, Liu H, Trepicchio WL, Eton O, Shepherd FA. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2009 Aug; 4(8):1002-9. PMID: 19633475.
    View in: PubMed
  6. Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9. PMID: 19430405.
    View in: PubMed
  7. Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008 Sep 2; 99(5):734-40. PMID: 18728664.
    View in: PubMed
  8. Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB. Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Res. 2008 Aug; 18(4):241-5. PMID: 18626307.
    View in: PubMed
  9. Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer. 2006 May 1; 106(9):2005-11. PMID: 16565971.
    View in: PubMed
  10. Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec). J Cutan Pathol. 2006 Apr; 33(4):280-5. PMID: 16630177.
    View in: PubMed
  11. Eton O. Chemotherapy, cytokines, and biochemotherapy for melanoma. Cancer Chemother Biol Response Modif. 2005; 22:739-48. PMID: 16110637.
    View in: PubMed
  12. Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer. 2004 Aug 1; 101(3):596-603. PMID: 15274073.
    View in: PubMed
  13. Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, Broemeling LD, Johnson MM, Ballo MT, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Prieto VG, Bedikian AY. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer. 2004 Apr 1; 100(7):1478-83. PMID: 15042682.
    View in: PubMed
  14. McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, Shtivelband M, Bar-Eli M. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol. 2004 Feb; 122(2):400-5. PMID: 15009722.
    View in: PubMed
  15. Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res. 2004 Feb; 14(1):63-6. PMID: 15091196.
    View in: PubMed
  16. Shen SS, Zhang PS, Eton O, Prieto VG. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol. 2003 Oct; 30(9):539-47. PMID: 14507401.
    View in: PubMed
  17. Bedikian AY, Papadopoulos N, Plager C, Eton O, Ring S. Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res. 2003 Jun; 13(3):303-6. PMID: 12777987.
    View in: PubMed
  18. Eton O, Rosenblum MG, Legha SS, Zhang W, Jo East M, Bedikian A, Papadopoulos N, Buzaid A, Benjamin RS. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Cancer. 2002 Jul 1; 95(1):127-34. PMID: 12115326.
    View in: PubMed
  19. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002 Apr 15; 20(8):2045-52. PMID: 11956264.
    View in: PubMed
  20. Ellerhorst JA, Bedikian AY, Smith TM, Papadopoulos NE, Plager C, Eton O. Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma. Anticancer Drugs. 2002 Feb; 13(2):169-72. PMID: 11901310.
    View in: PubMed
  21. Bedikian AY, Plager C, Stewart JR, O'Brian CA, Herdman SK, Ross M, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res. 2001 Apr; 11(2):183-8. PMID: 11333129.
    View in: PubMed
  22. Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O, Buzaid AC. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res. 2000 Oct; 6(10):3895-903. PMID: 11051235.
    View in: PubMed
  23. Eton O, Buzaid AC, Bedikian AY, Smith TM, Papadopoulos NE, Ellerhorst JA, Hibberts JL, Legha SS, Benjamin RS. A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy. Cancer. 2000 Apr 1; 88(7):1703-9. PMID: 10738230.
    View in: PubMed
  24. Eton O, East M, Legha SS, Bedikian A, Buzaid AC, Papadopoulos N, Hodges C, Gianan M, Carrasco CH, Benjamin RS. Pilot study of intra-arterial cisplatin and intravenous vinblastine and dacarbazine in patients with melanoma in-transit metastases. Melanoma Res. 1999 Oct; 9(5):483-9. PMID: 10596915.
    View in: PubMed
  25. Bedikian AY, Legha SS, Eton O, Buzaid AC, Papadopoulos N, Plager C, McIntyre S, Viallet J. Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma. Anticancer Drugs. 1999 Sep; 10(8):735-9. PMID: 10573206.
    View in: PubMed
  26. Ellerhorst JA, Bedikian A, Ring S, Buzaid AC, Eton O, Legha SS. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. Oncol Rep. 1999 Sep-Oct; 6(5):1097-9. PMID: 10425308.
    View in: PubMed
  27. Buzaid AC, Colome M, Bedikian A, Eton O, Legha SS, Papadopoulos N, Plager C, Ross M, Lee JE, Mansfield P, Rice J, Ring S, Lee JJ, Strom E, Benjamin R. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res. 1998 Dec; 8(6):549-56. PMID: 9918417.
    View in: PubMed
  28. Pride MW, Shuey S, Grillo-Lopez A, Braslawsky G, Ross M, Legha SS, Eton O, Buzaid A, Ioannides C, Murray JL. Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. Clin Cancer Res. 1998 Oct; 4(10):2363-70. PMID: 9796966.
    View in: PubMed
  29. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998 May; 16(5):1752-9. PMID: 9586888.
    View in: PubMed
  30. Buzaid AC, Ali-Osman F, Akande N, Grimm EA, Lee JJ, Bedikian A, Eton O, Papadopoulos N, Plager C, Legha SS, Benjamin RS. DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. Melanoma Res. 1998 Apr; 8(2):145-8. PMID: 9610867.
    View in: PubMed
  31. Anderson CM, Buzaid AC, Sussman J, Lee JJ, Ali-Osman F, Braunschweiger PG, Plager C, Bedikian A, Papadopoulos N, Eton O, Legha SS, Grimm EA. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. Melanoma Res. 1998 Apr; 8(2):149-55. PMID: 9610868.
    View in: PubMed
  32. Eton O, Kharkevitch DD, Gianan MA, Ross MI, Itoh K, Pride MW, Donawho C, Buzaid AC, Mansfield PF, Lee JE, Legha SS, Plager C, Papadopoulos NE, Bedikian AY, Benjamin RS, Balch CM. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. Clin Cancer Res. 1998 Mar; 4(3):619-27. PMID: 9533529.
    View in: PubMed
  33. Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, Burgess AM, Bedikian AY, Ring S, Dong Q, Glassman AB, Balch CM, Benjamin RS. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol. 1998 Mar; 16(3):1103-11. PMID: 9508197.
    View in: PubMed
  34. Yeung SC, Eton O, Burton DW, Deftos LJ, Vassilopoulou-Sellin R, Gagel RF. Hypercalcemia due to parathyroid hormone-related protein secretion by melanoma. Horm Res. 1998; 49(6):288-91. PMID: 9623520.
    View in: PubMed
  35. Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Cancer J Sci Am. 1997 Dec; 3 Suppl 1:S9-15. PMID: 9457387.
    View in: PubMed
  36. Bedikian AY, Legha SS, Eton O, Buzaid AC, Papadopoulos N, Coates S, Simmons T, Neefe J, von Roemeling R. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann Oncol. 1997 Apr; 8(4):363-7. PMID: 9209666.
    View in: PubMed
  37. Buzaid AC, Ross MI, Balch CM, Soong S, McCarthy WH, Tinoco L, Mansfield P, Lee JE, Bedikian A, Eton O, Plager C, Papadopoulos N, Legha SS, Benjamin RS. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 1997 Mar; 15(3):1039-51. PMID: 9060544.
    View in: PubMed
  38. Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, Papadopoulos N. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol. 1996 Oct; 7(8):827-35. PMID: 8922197.
    View in: PubMed
  39. Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K, Rieger PT, Saleh M, Khazaeli MB, Vadhan-Raj S. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1996 May; 19(3):206-17. PMID: 8811495.
    View in: PubMed
  40. Eton O, Talpaz M, Lee KH, Rothberg JM, Brell JM, Benjamin RS. Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma. Cancer. 1996 Mar 1; 77(5):893-9. PMID: 8608480.
    View in: PubMed
  41. Legha SS, Gianan MA, Plager C, Eton OE, Papadopoulous NE. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer. 1996 Jan 1; 77(1):89-96. PMID: 8630945.
    View in: PubMed
  42. Bedikian AY, Weiss GR, Legha SS, Burris HA, Eckardt JR, Jenkins J, Eton O, Buzaid AC, Smetzer L, Von Hoff DD, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol. 1995 Dec; 13(12):2895-9. PMID: 8523052.
    View in: PubMed
  43. Tyler DS, Francis GM, Frederick M, Tran AH, Ordóñez NG, Smith JL, Eton O, Ross M, Grimm EA. Interleukin-1 production in tumor cells of human melanoma surgical specimens. J Interferon Cytokine Res. 1995 Apr; 15(4):331-40. PMID: 7627808.
    View in: PubMed
  44. Buzaid AC, Grimm EA, Ali-Osman F, Ring S, Eton O, Papadopoulos NE, Bedikian A, Plager C, Legha SS, Benjamin R. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. Melanoma Res. 1994 Oct; 4(5):327-30. PMID: 7858418.
    View in: PubMed
  45. Umezu Y, Augustus LB, Seito D, Hayakawa K, Ross MI, Eton O, Swanson DA, Itoh K. Increase in the ability of human cancer cells to induce cytotoxic T lymphocytes by ultraviolet irradiation. Cancer Immunol Immunother. 1993 Nov; 37(6):392-9. PMID: 8242664.
    View in: PubMed
  46. Eton O, Legha SS, Balch CM. Cutaneous melanoma. N Engl J Med. 1992 Jan 30; 326(5):345-6; author reply 346-7. PMID: 1728744.
    View in: PubMed
  47. Eton O, Bajorin DF, Chapman PB, Cody BV, Houghton AN. Phase II trial of cisplatin and etoposide in patients with metastatic melanoma. Invest New Drugs. 1991 Feb; 9(1):101-3. PMID: 2026478.
    View in: PubMed
  48. Eton O, Bajorin DF, Casper ES, Houghton AN. Phase II trial of N-methylformamide in patients with metastatic melanoma. Invest New Drugs. 1991 Feb; 9(1):97-100. PMID: 2026491.
    View in: PubMed
  49. Eton O, Scheinberg DA, Houghton AN. Establishment and characterization of two human myeloma cell lines secreting kappa light chains. Leukemia. 1989 Oct; 3(10):729-35. PMID: 2506399.
    View in: PubMed
Omar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Similar BU People
_
Same Department